title: Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
abstract: There is a critical need to identify treatment options for patients at high risk for developing muscle invasive bladder cancer that avoid surgical removal of the bladder (cystectomy). In the current study, we have performed preclinical studies to investigate the efficacy of intravesical delivery of chemotherapy for preventing progression of bladder cancer. We evaluated three chemotherapy agents, namely cisplatin, gemcitabine, and docetaxel, which are currently in use clinically for systemic treatment of muscle invasive bladder cancer and/or have been evaluated for intravesical therapy. These preclinical studies were done using a genetically-engineered mouse (GEM) model that progresses from carcinoma in situ (CIS) to invasive, metastatic bladder cancer. We performed intravesical treatment in this GEM model using cisplatin, gemcitabine, and/or docetaxel, alone or by combining two agents, and evaluated whether such treatments inhibited progression to invasive, metastatic bladder cancer. Of the three single agents tested, gemcitabine was most effective for preventing progression to invasive disease, as assessed by several relevant endpoints. However, the combinations of two agents, and particularly those including gemcitabine, were more effective for reducing both tumor and metastatic burden. Our findings suggest combination intravesical chemotherapy may provide a viable bladder-sparing treatment alternative for patients at high risk for developing invasive bladder cancer, which can be evaluated in appropriate clinical trials.
authors.affiliation: Department of Urology, Columbia University Medical Center, New York, NY, USA.
authors.forename: Joan C
authors.initials: JC
authors.lastname: Delto
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Mitchell
authors.initials: M
authors.lastname: Benson
authors.forename: James
authors.initials: J
authors.lastname: McKiernan
authors.forename: Cory
authors.initials: C
authors.lastname: Abate-Shen
mesh_terms: D000283:Administration, Intravesical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003515:Cycloleucine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004195:Disease Models, Animal; D018450:Disease Progression; D000077143:Docetaxel; D004354:Drug Screening Assays, Antitumor; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D003515:Cycloleucine; D003841:Deoxycytidine; D000077143:Docetaxel; C065594:cispentacin; D000093542:Gemcitabine
references.citation: Ann Oncol. 2006 Sep;17 Suppl 10:x23-30
references.pmid: 17018729
references.citation: Urology. 2004 Oct;64(4):845-8
references.pmid: 15491745
references.citation: Cancer Cell. 2004 Aug;6(2):111-6
references.pmid: 15324694
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3075-80
references.pmid: 16809732
references.citation: J Urol. 2007 Dec;178(6):2314-30
references.pmid: 17993339
references.citation: Urology. 2010 Jan;75(1):134-7
references.pmid: 19913890
references.citation: Urol Oncol. 2010 Jul-Aug;28(4):409-28
references.pmid: 20610279
references.citation: Urol Oncol. 2010 Jul-Aug;28(4):401-8
references.pmid: 20610278
references.citation: J Clin Oncol. 2006 Dec 10;24(35):5519-27
references.pmid: 17158537
references.citation: Anticancer Drugs. 2007 Feb;18(2):211-8
references.pmid: 17159607
references.citation: Cancer Prev Res (Phila). 2009 Dec;2(12):1008-14
references.pmid: 19952358
references.citation: J Clin Invest. 2008 Sep;118(9):3051-64
references.pmid: 18725989
references.citation: Genes Dev. 2009 Mar 15;23(6):675-80
references.pmid: 19261747
references.citation: N Engl J Med. 2003 Aug 28;349(9):859-66
references.pmid: 12944571
references.citation: BJU Int. 2008 Jun;101(11):1347-55
references.pmid: 18384637
references.citation: J Clin Oncol. 2003 Feb 15;21(4):697-703
references.pmid: 12586808
references.citation: BJU Int. 2007 Dec;100(6):1377-84
references.pmid: 17850390
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2729-34
references.pmid: 16782913
references.citation: Eur Urol. 2004 Feb;45(2):182-6
references.pmid: 14734004
references.citation: Urol Oncol. 2010 Jul-Aug;28(4):429-40
references.pmid: 20610280
references.citation: Lancet. 2009 Jul 18;374(9685):239-49
references.pmid: 19520422
references.citation: Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S199-205
references.pmid: 20019985
references.citation: Cancer. 1989 Dec 15;64(12):2448-58
references.pmid: 2819654
references.citation: Biomacromolecules. 2011 Apr 11;12(4):949-60
references.pmid: 21355626
references.citation: J Urol. 2005 Sep;174(3):1115-8
references.pmid: 16094076